U.S. markets open in 5 hours 59 minutes
  • S&P Futures

    4,343.25
    -60.50 (-1.37%)
     
  • Dow Futures

    33,941.00
    -312.00 (-0.91%)
     
  • Nasdaq Futures

    14,233.25
    -267.75 (-1.85%)
     
  • Russell 2000 Futures

    2,003.90
    -27.80 (-1.37%)
     
  • Crude Oil

    83.67
    +0.36 (+0.43%)
     
  • Gold

    1,842.60
    +0.90 (+0.05%)
     
  • Silver

    23.83
    +0.03 (+0.15%)
     
  • EUR/USD

    1.1311
    -0.0019 (-0.17%)
     
  • 10-Yr Bond

    1.7350
    0.0000 (0.00%)
     
  • Vix

    32.34
    +3.49 (+12.10%)
     
  • GBP/USD

    1.3483
    -0.0008 (-0.06%)
     
  • USD/JPY

    113.8390
    -0.1210 (-0.11%)
     
  • BTC-USD

    36,273.90
    +1,181.77 (+3.37%)
     
  • CMC Crypto 200

    824.19
    +13.59 (+1.68%)
     
  • FTSE 100

    7,351.48
    +54.33 (+0.74%)
     
  • Nikkei 225

    27,131.34
    -457.03 (-1.66%)
     

electroCore to Participate at Canaccord Genuity MedTech & Diagnostics Forum

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • ECOR

ROCKAWAY, NJ, Nov. 11, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will be available for virtual one-on-one meetings at the Canaccord Genuity MedTech & Diagnostics Forum. The conference is taking place virtually November 18, 2021. Details are as follows:

Canaccord Genuity MedTech & Diagnostics Forum:
Date: Thursday, November 18, 2021
Event: One-on-one meetings

Please contact your Canaccord Genuity representative if interested in arranging a one-on-one meeting with electroCore management during the event.

About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company's current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.

For more information, visit www.electrocore.com.

CONTACT: Investors: Rich Cockrell CG Capital 404-736-3838 ecor@cg.capital or Media Contact: Jackie Dorsky electroCore 908-313-6331 Jackie.dorsky@electrocore.com